SUNHO(China)BioPharmaceutical CO., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-32
RECRUITING5
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO33%
Delay Index: of 6 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open SUNHO(China)BioPharmaceutical CO., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| IAP0971 NCT06255964 |
P1/2 | Not yet recruiting | Bladder Cancer | 236 | 2024-10-07 |
| IBB0979 NCT05991583 |
P1/2 | Recruiting | Advanced Malignant Tumors | 25 | 2025-11-30 (+17 mo) |
| IAP0971 NCT06223841 |
P1/2 | Recruiting | Advanced Malignant Tumors | 50 | 2026-03-01 |
| IAE0972+ Methotrexate NCT06719479 |
P2/3 | Not yet recruiting | NPC; HNSCC | 60 | 2028-01-01 |
| IAH0968 NCT06504732 |
P2/3 | Recruiting | Stomach Neoplasms; Solid Tumor | 574 | 2028-07 (+24 mo) |
| IBB0979 NCT07076095 |
P2 | Not yet recruiting | Small Cell Lung Cancer | 200 | 2028-08-01 |
| IAP0971 NCT06581419 |
P1/2 | Recruiting | Advanced Malignant Neoplasm; Advanced or Metastatic Non-small Cell Lung Cancer | 78 | 2029-08-01 |
| IBD0333 NCT06292208 |
P1/2 | Recruiting | MTD | 48 | 2029-12-31 |